Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Citi
McKinsey
AstraZeneca
Johnson and Johnson
Cerilliant
Express Scripts
Deloitte
Dow

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021641

« Back to Dashboard

NDA 021641 describes AZILECT, which is a drug marketed by Teva and is included in one NDA. It is available from four suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the AZILECT profile page.

The generic ingredient in AZILECT is rasagiline mesylate. There are eighteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the rasagiline mesylate profile page.
Summary for 021641
Tradename:AZILECT
Applicant:Teva
Ingredient:rasagiline mesylate
Patents:2
Therapeutic Class:Antiparkinson Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 021641
Mechanism of ActionMonoamine Oxidase Inhibitors
Suppliers and Packaging for NDA: 021641
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
AZILECT rasagiline mesylate TABLET;ORAL 021641 NDA AUTHORIZED GENERIC Teva Pharmaceuticals USA, Inc. 0093-3060 N 0093-3060-56
AZILECT rasagiline mesylate TABLET;ORAL 021641 NDA AUTHORIZED GENERIC Teva Pharmaceuticals USA, Inc. 0093-3061 N 0093-3061-56

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 0.5MG BASE
Approval Date:May 16, 2006TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Dec 5, 2026Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Aug 27, 2027Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF PARKINSON'S DISEASE

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 1MG BASE
Approval Date:May 16, 2006TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Dec 5, 2026Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021641

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-001 May 16, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-001 May 16, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-002 May 16, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Teva AZILECT rasagiline mesylate TABLET;ORAL 021641-002 May 16, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Fish and Richardson
AstraZeneca
UBS
Harvard Business School
Healthtrust
McKesson
Queensland Health
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.